180,729 Shares in Qiagen (NYSE:QGEN) Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc bought a new position in Qiagen (NYSE:QGEN) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 180,729 shares of the company’s stock, valued at approximately $8,236,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its holdings in Qiagen by 62.6% in the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after acquiring an additional 991,325 shares in the last quarter. Atria Investments Inc grew its holdings in Qiagen by 6.0% during the 3rd quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock valued at $348,000 after buying an additional 433 shares in the last quarter. US Bancorp DE grew its holdings in Qiagen by 0.8% during the 3rd quarter. US Bancorp DE now owns 69,122 shares of the company’s stock valued at $3,150,000 after buying an additional 580 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Qiagen by 39.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 12,184 shares of the company’s stock valued at $550,000 after buying an additional 3,474 shares in the last quarter. Finally, Private Advisor Group LLC grew its holdings in Qiagen by 8.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock valued at $285,000 after buying an additional 461 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Robert W. Baird increased their target price on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Stock Down 1.9 %

Shares of QGEN opened at $41.28 on Friday. The company has a market cap of $9.42 billion, a PE ratio of 105.85, a P/E/G ratio of 3.24 and a beta of 0.41. The business has a fifty day moving average of $43.85 and a 200 day moving average of $43.75. Qiagen has a 52-week low of $39.03 and a 52-week high of $47.44. The company has a quick ratio of 1.46, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.